The Progression-Free Survival Of The First-Line Egfr-Tki Is A Strong Prognosticator Of The Second-Line Osimertinib In Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr-T790m Mutation: A Real-World Study

As a third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is recommended as standardized treatment for advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation after progressed on first-line EGFR-TKI. Our study aims to investigate the prognostic value of first-line EGFR-TKI on the second-line osimertinib in the real-world practice.